Filing search / Centessa Pharmaceuticals plc / "Assessment"

424B5

CNTA Centessa Pharmaceuticals plc

13 Sep 24

Prospectus supplement for primary offering

4:02pm

, a placebo-controlled S-2 cross-over pharmacodynamic (“PD”) assessment is being performed utilizing the MWT and Karolinska Sleepiness Scale (“KSS … , and has advanced through two cohorts within the cross-over assessment of acutely sleep-deprived healthy volunteers with doses of 1.0 mg (n=8) and 2.5

8-K

EX-1.1

CNTA Centessa Pharmaceuticals plc

13 Sep 24

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

4:00pm

they are liable and any related or similar assessment, fine or penalty levied against them (except for cases in which the failure to pay would

424B5

CNTA Centessa Pharmaceuticals plc

11 Sep 24

Prospectus supplement for primary offering

4:40pm

in healthy adult subjects. In parallel to the SAD, a placebo-controlled S-2 cross-over pharmacodynamic (“PD”) assessment is being performed utilizing … , 9 placebo) with doses of 1.0 mg, 2.0 mg, and 2.5 mg, and has advanced through two cohorts within the cross-over assessment of acutely sleep-deprived

S-3ASR

CNTA Centessa Pharmaceuticals plc

11 Sep 24

Automatic shelf registration

4:01pm

indenture; whether and under what circumstances we will pay any additional amounts on the debt securities in respect of any tax, assessment … . However, we will not be required to pay, discharge or cause to be paid or discharged any such tax, assessment, charge or claim whose amount

S-3ASR

EX-4.6

CNTA Centessa Pharmaceuticals plc

11 Sep 24

Automatic shelf registration

4:01pm

the Company or any successor, under any rule of law, statute, constitutional provision or by the enforcement of any assessment or penalty, or by any legal … amounts on such Securities in respect of any tax, assessment or governmental charge and, if so, whether the Company will have the option to redeem

S-3ASR

EX-4.4

6a8b76yr2e37vc

11 Sep 24

Automatic shelf registration

4:01pm

8-K

EX-99.1

fkvld txerrregnv6

10 Sep 24

Regulation FD Disclosure

7:08am

8-K

EX-99.2

omgocr1k0taxymn

10 Sep 24

Regulation FD Disclosure

7:08am

8-K

EX-99.1

70qpcf3ao2nibx3n3zz

13 Aug 24

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for Anticipated Upcoming Program Milestones

7:15am

DEFA14A

87ye g9eo5

20 May 24

Additional proxy soliciting materials

8:48pm

PRE 14A

fdxggk1

26 Apr 24

Preliminary proxy

4:36pm

424B5

u5rm2

24 Apr 24

Prospectus supplement for primary offering

8:53pm

8-K

EX-1.1

qwflhnp0czwvy3md

24 Apr 24

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

9:26am

424B5

1lczhq

23 Apr 24

Prospectus supplement for primary offering

5:16pm

8-K

iz05jtyihl7lmtre

22 Apr 24

Regulation FD Disclosure

7:15am

8-K

EX-99.1

wdcqgc

22 Apr 24

Regulation FD Disclosure

7:15am